What's happened?
Bod Australia Limited (“Bod", ASX: BDA) has received an import licence for two new medical cannabis products.
What are the details?
The new products expand the offering to now include a CBD isolate in 2.5% and 10% strengths. The CBD isolates are developed from Bod’s exclusive full plant extract. The extract is part of Bod's successful MediCabilis™ 5% CBD offering. Its safety, tolerability and pharmacokinetics have been proven in clinical trial settings and in over 2,000 prescriptions in Australia over the past 12 months.
Why is this significant?
Bod now has three MediCabilis™ products to offer approved prescribers and patients. The introduction of the 2.5% and 10% CBD Isolates allow Bod to target approximately an additional 32% of the total medicinal cannabis prescription market in Australia.
Bod believes that Bod’s MediCabilis™ product suite now gives physicians and patients greater product alternatives when seeking treatment. Bod is confident prescription volumes will increase in the coming months.
